A C Easty1, N Coakley2, R Cheng3, M Cividino4, P Savage5, R Tozer6, R E White7. 1. Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON. ; Centre for Global eHealth Innovation, University Health Network and University of Toronto, Toronto, ON. 2. Cancer Care Ontario, Program in Evidence-Based Care, Hamilton, ON. ; Department of Oncology, McMaster University, Hamilton, ON. 3. Institute for Safe Medication Practices Canada (ISMP Canada), Toronto, ON. 4. Public Health Ontario, Hamilton ON. ; St. Joseph's Healthcare, Hamilton, ON. 5. Princess Margaret Cancer Centre, Toronto, ON. 6. Juravinski Hospital, Hamilton, ON. ; Department of Oncology, McMaster University, Hamilton, ON. 7. Centre for Global eHealth Innovation, University Health Network and University of Toronto, Toronto, ON.
Abstract
BACKGROUND: This evidence-based practice guideline was developed to update and address new issues in the handling of cytotoxics, including the use of oral cytotoxics; the selection and use of personal protective equipment; and treatment in diverse settings, including the home setting. METHODS: The guideline was developed primarily from an adaptation and endorsement of an existing guideline and from three systematic reviews. Before publication, the guideline underwent a series of peer and external reviews to gather feedback. All comments were addressed, and the guideline was amended when required. The guideline applies to health care workers who could come into contact with cytotoxic drugs at any point in the medication circuit. The intended users are hospital administrators, educators, and managers; occupational health and safety services; and pharmacy and health care workers. RESULTS: The recommendations represent a reasonable and practical set of procedures that the intended users of this guideline should implement to minimize opportunities for accidental exposure. They are not limited to just the point of care; they cover the entire chain of cytotoxics handling from the time such agents enter the institution until they leave in the patient or as waste. CONCLUSIONS: Reducing the likelihood of accidental exposure to cytotoxic agents within the medication circuit is the main objective of this evidenced-based guideline. The recommendations differ slightly from earlier guidelines because of the availability of new evidence.
BACKGROUND: This evidence-based practice guideline was developed to update and address new issues in the handling of cytotoxics, including the use of oral cytotoxics; the selection and use of personal protective equipment; and treatment in diverse settings, including the home setting. METHODS: The guideline was developed primarily from an adaptation and endorsement of an existing guideline and from three systematic reviews. Before publication, the guideline underwent a series of peer and external reviews to gather feedback. All comments were addressed, and the guideline was amended when required. The guideline applies to health care workers who could come into contact with cytotoxic drugs at any point in the medication circuit. The intended users are hospital administrators, educators, and managers; occupational health and safety services; and pharmacy and health care workers. RESULTS: The recommendations represent a reasonable and practical set of procedures that the intended users of this guideline should implement to minimize opportunities for accidental exposure. They are not limited to just the point of care; they cover the entire chain of cytotoxics handling from the time such agents enter the institution until they leave in the patient or as waste. CONCLUSIONS: Reducing the likelihood of accidental exposure to cytotoxic agents within the medication circuit is the main objective of this evidenced-based guideline. The recommendations differ slightly from earlier guidelines because of the availability of new evidence.
Entities:
Keywords:
Cytotoxic drugs; cytotoxic drug administration; cytotoxic drug preparation; guidelines; hazardous waste; personal protective equipment
Authors: Christina C Lawson; Carissa M Rocheleau; Elizabeth A Whelan; Eileen N Lividoti Hibert; Barbara Grajewski; Donna Spiegelman; Janet W Rich-Edwards Journal: Am J Obstet Gynecol Date: 2011-12-30 Impact factor: 8.661
Authors: B Favier; H Labrosse; L Gilles-Afchain; C Cropet; D Perol; N Chaumard; J F Latour; P Hild Journal: J Oncol Pharm Pract Date: 2011-03-21 Impact factor: 1.809
Authors: Andrew C Seger; William W Churchill; Carol A Keohane; Caryn D Belisle; Stephanie T Wong; Katelyn W Sylvester; Megan A Chesnick; Elisabeth Burdick; Matt F Wien; Michael C Cotugno; David W Bates; Jeffrey M Rothschild Journal: J Oncol Pract Date: 2012-09-25 Impact factor: 3.840
Authors: G P Browman; M N Levine; E A Mohide; R S Hayward; K I Pritchard; A Gafni; A Laupacis Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: G P Browman; T E Newman; E A Mohide; I D Graham; M N Levine; K I Pritchard; W K Evans; J A Maroun; D I Hodson; M S Carey; D H Cowan Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544
Authors: Pan Shu; Ting Zhao; Bo Wen; Kari Mendelsohn-Victor; Duxin Sun; Christopher R Friese; Manjunath P Pai Journal: J Oncol Pharm Pract Date: 2019-09-04 Impact factor: 1.809
Authors: Mari A Bernabeu-Martínez; Mateo Ramos Merino; Juan M Santos Gago; Luis M Álvarez Sabucedo; Carmina Wanden-Berghe; Javier Sanz-Valero Journal: PLoS One Date: 2018-05-11 Impact factor: 3.240